Rauch Bernhard, Davos Constantinos H, Doherty Patrick, Saure Daniel, Metzendorf Maria-Inti, Salzwedel Annett, Völler Heinz, Jensen Katrin, Schmid Jean-Paul
1 Institut für Herzinfarktforschung Ludwigshafen, Germany.
2 Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Greece.
Eur J Prev Cardiol. 2016 Dec;23(18):1914-1939. doi: 10.1177/2047487316671181. Epub 2016 Oct 25.
Background The prognostic effect of multi-component cardiac rehabilitation (CR) in the modern era of statins and acute revascularisation remains controversial. Focusing on actual clinical practice, the aim was to evaluate the effect of CR on total mortality and other clinical endpoints after an acute coronary event. Design Structured review and meta-analysis. Methods Randomised controlled trials (RCTs), retrospective controlled cohort studies (rCCSs) and prospective controlled cohort studies (pCCSs) evaluating patients after acute coronary syndrome (ACS), coronary artery bypass grafting (CABG) or mixed populations with coronary artery disease (CAD) were included, provided the index event was in 1995 or later. Results Out of n = 18,534 abstracts, 25 studies were identified for final evaluation (RCT: n = 1; pCCS: n = 7; rCCS: n = 17), including n = 219,702 patients (after ACS: n = 46,338; after CABG: n = 14,583; mixed populations: n = 158,781; mean follow-up: 40 months). Heterogeneity in design, biometrical assessment of results and potential confounders was evident. CCSs evaluating ACS patients showed a significantly reduced mortality for CR participants (pCCS: hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.20-0.69; rCCS: HR 0.64, 95% CI 0.49-0.84; odds ratio 0.20, 95% CI 0.08-0.48), but the single RCT fulfilling Cardiac Rehabilitation Outcome Study (CROS) inclusion criteria showed neutral results. CR participation was also associated with reduced mortality after CABG (rCCS: HR 0.62, 95% CI 0.54-0.70) and in mixed CAD populations. Conclusions CR participation after ACS and CABG is associated with reduced mortality even in the modern era of CAD treatment. However, the heterogeneity of study designs and CR programmes highlights the need for defining internationally accepted standards in CR delivery and scientific evaluation.
背景 在他汀类药物和急性血运重建的现代时代,多组分心脏康复(CR)的预后效果仍存在争议。着眼于实际临床实践,目的是评估CR对急性冠脉事件后总死亡率和其他临床终点的影响。
设计 结构化综述和荟萃分析。
方法 纳入评估急性冠脉综合征(ACS)、冠状动脉旁路移植术(CABG)后患者或冠心病(CAD)混合人群的随机对照试验(RCT)、回顾性对照队列研究(rCCS)和前瞻性对照队列研究(pCCS),前提是索引事件发生在1995年或之后。
结果 在n = 18,534篇摘要中,确定了25项研究进行最终评估(RCT:n = 1;pCCS:n = 7;rCCS:n = 17),包括n = 219,702例患者(ACS后:n = 46,338;CABG后:n = 14,583;混合人群:n = 158,781;平均随访:40个月)。设计、结果的生物统计学评估和潜在混杂因素方面的异质性很明显。评估ACS患者的CCS显示,CR参与者的死亡率显著降低(pCCS:风险比(HR)0.37,95%置信区间(CI)0.20 - 0.69;rCCS:HR 0.64,95% CI 0.49 - 0.84;优势比0.20,95% CI 0.08 - 0.48),但符合心脏康复结局研究(CROS)纳入标准的单一RCT显示结果为中性。CR参与也与CABG后和混合CAD人群的死亡率降低相关。
结论 即使在CAD治疗的现代时代,ACS和CABG后参与CR也与死亡率降低相关。然而,研究设计和CR方案的异质性凸显了在CR实施和科学评估中定义国际公认标准的必要性。